Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
70.91
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
70.91
Bid (Size)
66.00 (1)
Ask (Size)
113.23 (2)
Prev. Close
70.91
Today's Range
70.91 - 70.91
52wk Range
53.12 - 77.72
Shares Outstanding
166,301,231
Dividend Yield
1.38%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
March 19, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Performance
YTD
+0.11%
+0.11%
1 Month
-2.92%
-2.92%
3 Month
+4.05%
+4.05%
6 Month
+5.51%
+5.51%
1 Year
+17.61%
+17.61%
More News
Read More
Dr. Reddy’s Q3 & 9M FY24 Financial Results
January 31, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr Reddy's Laboratories: Q3 Earnings Insights
January 30, 2024
Via
Benzinga
Is NYSE:RDY suited for quality investing?
September 14, 2023
Via
Chartmill
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
January 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
December 14, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Should you consider NYSE:RDY for quality investing?
August 21, 2023
Via
Chartmill
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
Via
MarketBeat
Exposures
Product Safety
Dr. Reddy’s Q2 FY24 Financial Results
October 27, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities.
October 24, 2023
Via
Chartmill
Chart Of The Day: What's Cooking At Dr. Reddy's Lab
July 28, 2023
Via
Talk Markets
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
Via
Benzinga
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
August 10, 2023
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1 FY24 Financial Results
July 26, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
July 12, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Why Are Journey Medical Shares Trading Lower Today?
July 11, 2023
Via
Benzinga
Drugmaker GSK: Becoming a Healthier Value Stock
June 27, 2023
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Why Are Journey Medical Shares Trading Higher Today
June 13, 2023
Via
Benzinga
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
June 05, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
The 3 Most Undervalued Value Stocks to Buy in June 2023
June 04, 2023
Via
InvestorPlace
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Via
Talk Markets
Dr. Reddy’s Q4 & FY23 Financial Results
May 10, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
May 05, 2023
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
